05th week of 2021 patent applcation highlights part 9 |
Patent application number | Title | Published |
20210030664 | TREATMENT OF IMMUNE DISEASES BY ADMINISTRATION OF ANTIGEN-SPECIFIC FORMULATIONS - The present invention relates to the treatment of autoimmune and allergic diseases by oromucosal administration of a formulation consisting of an optimized combination of antigen, tolerizing agent and mucoadhesive carrier for each immune disease indication. | 2021-02-04 |
20210030665 | SYNTHETIC TRANSDERMAL CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS - The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced. | 2021-02-04 |
20210030666 | PROGESTERONE INTRAVAGINAL DEVICES - The invention relates to intravaginal devices, in particular rings, comprising progesterone in a particular polymorphic purity, methods for making such devices and therapeutic uses of said devices. In particular, the intravaginal devices comprise a high amount of progesterone polymorph I and are useful in the treatment of infertility in a female subject. | 2021-02-04 |
20210030667 | OCULAR INSERTS COMPRISING A COVALENTLY LINKED STEROID DIMER - The disclosure relates to compounds and compositions for sustained release of ocular therapeutics. | 2021-02-04 |
20210030668 | MULTI-LAYER ORAL THIN FILM - Described are: a multi-layer oral thin film, comprising at least two layers arranged one on top of the other, which each comprise at least one water-soluble polymer, these at least two layers being connected to one another by at least one sealing, characterised in that the at least one sealing is not provided over the entire surface; a method for producing same; and use thereof as a medicament. | 2021-02-04 |
20210030669 | GASTROINTESTINAL SITE-SPECIFIC ORAL VACCINATION FORMULATIONS ACTIVE ON THE ILEUM AND APPENDIX - The invention provides oral vaccine formulations which deliver an antigen in the vicinity of the distal ileum and the area of the ileal Brake and/or the appendix. These vaccines are useful in the treatment and/or prevention of variety of disorders, including viral and bacterial infections and cancers. Related methods of treatment which use the oral vaccine formulations of the invention are also provided. | 2021-02-04 |
20210030670 | NOVEL ANTIARRHYTHMIC FORMULATION - Pharmaceutical compositions comprising an antiarrhythmic agent for treatment of a heart condition via inhalation. Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also disclosed. | 2021-02-04 |
20210030671 | LIQUID DOSAGE FORMS OF CINACALCET OR SALT THEREOF - Cinacalcet is approved and marketed as hydrochloride salt in a solid dosage form indicated for the treatment of secondary hyperparathyroidism resulting from chronic kidney disease and for the treatment of hypercalcemia in patients with either parathyroid carcinoma or hyperparathyroidism. Current marketed products are not allowed to be divided and to be taken whole during administration. Patients having swallowing difficulty may not show adherence to such regimen. The present invention therefore provides liquid dosage forms of Cinacalcet or pharmaceutically acceptable salt thereof. | 2021-02-04 |
20210030672 | TOPICAL TREATMENT OF VITILIGO BY A JAK INHIBITOR - The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof. | 2021-02-04 |
20210030673 | Method and a Compound for Preventing Mammalian Cancer Cell Proliferation and for Treating Cancer - A composition and a method for use in suppressing growth and/or proliferation of cancer cells in vivo and in vitro is provided. The composition includes an alcoholic lignan extract prepared from coniferous species optionally in combination with betulonic acid or betulinic acid. The composition inhibits growth and/or proliferation of at least prostate and melanoma cancer cells in vitro. Combination of the alcoholic lignan extract and betulonic or betulinic acid has a synergic effect specifically in inhibition of melanoma and prostate cancer cell proliferation and toxicity. Oral daily administration of the composition decreases or in some cases abolishes tumors of patients with breast cancer, brain cancer or colon cancer. The composition is suitable for use in cancer treatment in pet animals as well. | 2021-02-04 |
20210030674 | INTRAVAGINAL FORMULATION - An intravaginal formulation comprising a dry powder composition and propellant(s) and the apparatus capable of delivery intravaginally a dry powder composition. | 2021-02-04 |
20210030675 | MESOPOROUS SILICA NANOPARTICLES AND SUPPORTED LIPID BI-LAYER NANOPARTICLES FOR BIOMEDICAL APPLICATIONS - The present disclosure is directed to methods of producing monosized protocells from monosized mesoporous silica nanoparticles (mMSNPs) and their use for targeted drug delivery formulations and systems and for biomedical applications. The present disclosure is also directed in part to a multilamellar or unilamellar protocell vaccine to deliver full length viral protein and/or plasmid encoded viral protein to antigen presenting cells (APCs) in order to induce an immunogenic response to a virus. | 2021-02-04 |
20210030676 | SHEAR STRESS SENSITIVE LIPOSOMES - A liposome vesicle comprising a membrane consisting of 1,3-diheptadecanamidopropan-2-yl(2-(trimethylammonio)ethyl)phosphate surrounding a volume comprising a pharmaceutical drug or contrast agent. The vesicle is mechanosensitive at body temperature and at physiologically or pathophysiologically relevant shear stress. | 2021-02-04 |
20210030677 | TREATMENT OF PNEUMONIA - The present invention relates to a composition comprising a mixture of empty liposomes, wherein said mixture of empty liposomes comprises (a) a first empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight); and (b) a second empty liposome comprising sphingomyelin, for use in adjunctive treatment of 5 pneumonia in a human patient. | 2021-02-04 |
20210030678 | CANNABINOID AND CBD LIPOSOME FORMULATIONS AND USES THEREOF - Aspects of the present application provide liposomal formulations of cannabinoid extracts. Method of using such formulation, e.g., for the treatment of inflammation are also provided. | 2021-02-04 |
20210030679 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR - Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics. | 2021-02-04 |
20210030680 | NANOPARTICLE COMPOSITIONS AND METHODS OF USE OF PARP INHIBITOR FOR TREATMENT OF CANCER - Described herein are methods of treatment of cancer by administering a therapeutically effective amount of a cytotoxic alkylating agent and a nanoparticle formulation containing an inhibitor of poly (ADP-ribose) polymerase 1. Also disclosed are treatment regimens involving parenteral administration of a therapeutically effective amount of a cytotoxic alkylating agent and a nanoparticle formulation containing an inhibitor of poly (ADP-ribose) polymerase 1. | 2021-02-04 |
20210030681 | MULTIPARTICULATE SOLID DOSAGE FORM HAVING AN ELASTIC TEXTURE - The present invention relates to a multiparticulate solid dosage form ( | 2021-02-04 |
20210030682 | PREPARATION OF SOLID DOSAGE FORMS COMPRISING ANTIBODIES BY SOLUTIONS/SUSPENSION LAYERING - The present invention relates to a method for preparing immediate and sustained release solid dosage forms, comprising antibodies and functional fragments thereof, by solution/suspension layering,optionally coated with a delayed release coating; the solid dosage forms prepared by the method; and the use of the solid dosage forms in the topical treatment in the gastrointestinal tract of a patient. | 2021-02-04 |
20210030683 | DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNA - The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule. | 2021-02-04 |
20210030684 | METHOD FOR PREPARING ADDITIVE-FREE CELL-WALL-BROKEN GRANULE OF CHINESE MEDICINAL MATERIAL - The present invention provides a method for preparing an additive-free cell-wall-broken granule of a Chinese medicinal material. The cell-wall-broken granule is obtained by medicinal material concocting and grinding, first cell-wall-breaking and grinding, screening, second wall-breaking and grinding, mixing, pelleting, and granulating and sieving. The obtained granule has a moderate tightness, a relatively rapid dissolution and diffusion and a good uniformity, overcoming problems of a difficulty of dissolution and diffusion and a poor uniformity of the existing cell-wall-broken granules. | 2021-02-04 |
20210030685 | PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASE - The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. In certain embodiments, the programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, and volume of gastric fluid. The programmable osmotic-controlled oral compositions of the disclosure comprise a multilayer core comprising a drug for controlled release, wherein the core is coated with a semipermeable membrane comprising an orifice and, optionally, an immediate release coating, comprising a drug for immediate release, over the semipermeable membrane. The multilayered core comprises a pull layer containing the drug and a push layer. The pull layer comprises at least two layers: a placebo layer for providing a desired lag time for the drug release; and an active layer containing the drug and providing a delayed controlled release of the drug. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition's symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects. | 2021-02-04 |
20210030686 | INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS - The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines. | 2021-02-04 |
20210030687 | PHARMACEUTICAL FORMULATION COMPRISING ESOMEPRAZOLE AND SODIUM BICARBONATE - The present invention relates to a stable pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention provides a stable formulation by preventing omeprazole, its enantiomer, or its pharmaceutically acceptable salt, from coming in direct contact with sodium bicarbonate, to reduce the production of impurities. | 2021-02-04 |
20210030688 | COATED BIOLOGICAL COMPOSITION - A coated biological composition has a mixture of biologic material and a volume of a liquid protectant. The mixture of biologic material has non-whole cellular components or whole cells or combinations of the non-whole cellular components and whole cells, wherein the mixture is compatible with biologic function. The volume of a liquid protectant is intermixed with the mixture of biologic material, wherein the liquid protectant forms a coating externally enveloping each of the non-whole cellular components, if any, and each of the whole cells, if any, of the mixture of biologic material, to form the coated biological composition. The coated biological composition is frozen and thereafter thawed and then frozen a second time for storage or frozen at least once and thawed and stored under refrigeration above freezing, or frozen and thawed and then concentrated by drying, or while frozen without thawing lyophilized for ambient or room temperature storage. | 2021-02-04 |
20210030689 | DECREASED ADHESIVITY RECEPTOR-TARGETED NANOPARTICLES FOR Fn14-POSITIVE TUMORS - Metastatic triple negative breast cancer (TNBC) still carries a dismal prognosis with the current treatment paradigms. The effectiveness of drug treatment for many solid tumors such as TNBC is limited by tumor heterogeneity, lack of tumor specificity, off-target toxicities, and transient therapeutic action(s). Strategies that provide tumor-specific, sustained concentrations of drugs to the tumors and tumor receptor-specific binding, while reducing off-target effects are needed to ensure sufficient tumor cell uptake within the primary and metastatic tumor microenvironment. The decreased non-specific adhesivity, receptor-targeted nanoparticle formulations (“DART” nanoparticles) of the invention were assessed for clinical potential in directing biological agents to the cell surface receptor Fn14, which is expressed in many solid cancer types, including TNBC primary tumors and metastatic lesions. They are contemplated for use against solid tumors, particularly brain tumors such as glioblastoma and breast cancer, including metastatic breast cancer. | 2021-02-04 |
20210030690 | MOLECULAR ENTRAPMENT VIA HOMOPOLYMER SELF-ASSEMBLY - The present invention provides novel nanostructures comprising solution of PPSU | 2021-02-04 |
20210030691 | DEOXYRIBONUCLEIC ACID NANOPARTICLES FOR DELIVERING PROTEINS AND PROTEIN-CONTAINING COMPOUNDS AND METHODS OF MANUFACTURING DEOXYRIBONUCLEIC ACID NANOPARTICLES - Non-viral delivery platforms are provided for facilitating transport of molecules across cell membranes. In some forms, DNA nanoshells capable of transporting cargo molecules are formed, and may be formed in order to surround a variety of materials for a variety of purposes. | 2021-02-04 |
20210030692 | POLYMERIC NANOPARTICLE COMPOSITIONS FOR ENCAPSULATION AND SUSTAINED RELEASE OF PROTEIN THERAPEUTICS - Described are new biodegradable nanoparticle platforms for encapsulation and sustained release of protein therapeutics through a scalable and reproducible method. Specifically nanoparticles comprising a complex comprising a protein, or peptide, and a counter ion polymer are described. | 2021-02-04 |
20210030693 | PHARMACEUTICAL ACTIVE-CONTAINING FILM DELIVERY DEVICE FOR ORAL TRANSMUCOSAL ADMINISTRATION - A transmucosal delivery device comprises a polymer film comprising a polymer matrix, and a pharmaceutical composition disposed on a surface of the polymer film, the composition comprising at least one pharmaceutical active, a binding polymer, a surfactant, a solubilizing solvent, and an anti-crystallization agent, wherein a dry concentration of the pharmaceutical active is greater than 10 wt % and the composition has a pH in a range of about 4 to about 8. The delivery device exhibits a residence time in the mouth of a subject ranging from about 5 minutes to about 15 minutes and is substantially mucoadhesive to a mucosal surface when placed sublingually under the tongue or placed buccally at the inner lining of the cheek of the subject. | 2021-02-04 |
20210030694 | Dermal Delivery Device - A transdermal drug delivery device is disclosed. Over an extended wear period, the device causes cumulative moderate irritation plus significant irritation of less than 5% and/or achieves a meaningful degree of detachment over a seven day period of less than 20%. | 2021-02-04 |
20210030695 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS - The invention provides compounds, compositions, methods, and kits for the treatment of neurogenic inflammation. | 2021-02-04 |
20210030696 | TREATMENT OF CHOLESTEROL CRYSTAL FORMATION - The invention relates to methods for disrupting cholesterol crystals and related methods for the prevention and/or treatment of disease. | 2021-02-04 |
20210030697 | Pharmaceutical Compositions Comprising a Statin and a Cannabinoid and Uses Thereof - The invention relates to pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis. It has been found that compositions combining a statin and a cannabinoid are improved over existing statin formulations. The compositions of the invention for example allow for a lower effective dose of statin and a reduction of the adverse effects seen with statins taken alone. Dosing ranges and formulations suitable for oral, buccal, and sublingual administration are disclosed. Various specific cannabinoids such as cannabidiol and synthetic cannabidiols selected for their anti-inflammatory, antioxidant, and anti-atherosclerotic effect are shown to be particularly advantageous. | 2021-02-04 |
20210030698 | GEL CONTAINING ZERUMBONE FROM BITTER GINGER (ZINGIBER ZERUMBET) FOR CURATIVE TREATMENT OF DIABETIC ULCERS - A dermatological pharmaceutical composition in the form of a gel (GZ) for topical use, produced by combining zerumbone (Z) from bitter ginger ( | 2021-02-04 |
20210030700 | COMPOSITION FOR PREVENTING AND TREATMENT OF SPINAL CORD INJURY - The present invention relates to a pharmaceutical composition comprising (S)-2-(((4′-trifluoromethylbiphenyl-4-yl)methyl)amino)propanamide methanesulfonate or a pharmaceutically acceptable salt thereof as an effective ingredient for prevention or treatment of spinal cord injury. | 2021-02-04 |
20210030701 | USE OF 1,3-PROPANEDISULFONIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OF SARCOIDOSIS - The present disclosure relates to methods for the treatment of sarcoidosis. In certain aspects and embodiments, the disclosure provides compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof and/or the use of such compositions for the treatment of Sarcoidosis. In another aspect, the disclosure relates to compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof plus a second active agent. In yet another aspect, the disclosure relates to kits containing agents useful for the treatment of sarcoidosis. | 2021-02-04 |
20210030702 | CARBON DIOXIDE EXTERNAL PREPARATION - Provided is a nonaqueous carbon dioxide external preparation in single dosage form, the external preparation comprising a paste base, carbonate, an acid and/or a substance which produces an acid by hydrolysis, and alcohol. Merely by being applied onto skin, this external preparation is useful due to obtaining the effect of a specific action of carbon dioxide. | 2021-02-04 |
20210030703 | USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS - In most cases, cancer chemotherapy and immunotherapy fail to yield durable responses, and complete and permanent regression of established tumors are rare. Here the inventors show that so-called caloric restriction mimetics (CRMs), which are natural or synthetic compounds that pharmacologically mimic the effects of fasting or caloric restriction, can be used to enhance the probability of cancer cure. The administration of several chemically distinct CRMs (such as hydroxycitrate, lipoic acid and the natural polyamine spermidine) led to the complete regression and the induction of protective anticancer immune responses in mouse models. This effect was achieved when CRMs were combined with chemotherapy and immunotherapy targeting the immune checkpoint molecules CTLA-4 and/or PD-1. Hence, caloric restriction and CRMs can be used to sensitize cancers to chemo-immunotherapy. | 2021-02-04 |
20210030704 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRAIN INJURY - Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury. | 2021-02-04 |
20210030705 | Pharmaceutical Solid Compositions Containing Ibuprofen Salts - A pharmaceutical, non-effervescent, solid composition comprising a mixture of a pharmaceutically effective amount of a ibuprofen salt and a pharmaceutically acceptable strong base in a molar ratio of from 1:0.01 to 1:0.8, said composition being such that, when dissolved in drinkable water for dilution, imparts a pH value ranging from 9 to 9.5 to the obtained solution, which do not cause sensory irritation to the oral cavity especially to the back of the mouth and throat, when swallowed. | 2021-02-04 |
20210030706 | METHODS AND COMPOSITIONS FOR TREATING INFECTION AND INFLAMMATION WITH SELENOCYANATE - The present invention generally relates to methods and compositions for treating pulmonary infections and inflammation with a composition comprising selenocyanate, hyposelenocyanite or a selenocyanate conjugate. | 2021-02-04 |
20210030707 | COMPOSITION CONTAINING EICOSAPENTAENOIC ACID ALKYL ESTER, AND METHOD FOR PRODUCING SAME - Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography. | 2021-02-04 |
20210030708 | Biologically Active Cannabidiol Analogs - Biologically active cannabidiol analogs comprising a compound of the formula | 2021-02-04 |
20210030709 | METHOD FOR TREATING PSORIASIS - A method for treating psoriasis including the steps of applying an isothiocyanate functional surfactant to an area affected by psoriasis, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. | 2021-02-04 |
20210030710 | ISOTHIOCYANATE FUNCTIONAL COMPOUNDS AUGMENTED WITH SECONDARY ANTINEOPLASTIC MEDICAMENTS AND ASSOCIATED METHODS FOR TREATING NEOPLASMS - A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent. | 2021-02-04 |
20210030711 | NASAL DRUG DELIVERY DEVICE AND METHOD OF MAKING SAME - A drug delivery device capable of forming a medicated mist that reaches the nasal and paranasal sinus cavities contains a puncturing element within its canister. The puncturing element is used in combination with a compartment that contains a filling. The compartment is optionally detachable from an interior of the device or entirely separate from the device. The puncturing element punctures the compartment, releasing the filling into the reservoir of the device to provide a medicated liquid. The device may store any form of medication so long as the medication remains stable. When dry powder forms are desired, the reservoir and/or compartment may be filled with a solution or diluent so as to form the medicated liquid, which may then be dispensed as a mist through the device following the puncturing. | 2021-02-04 |
20210030712 | WATER SOLUBLE CANNABIS COMPOSITION - The invention provides a water-soluble composition comprising | 2021-02-04 |
20210030713 | ANTHOCYANIDIN COMPLEX - The invention relates to a complex of an anthocyanidin and a methylated β-cyclodextrin which can be formulated as an aqueous solution and as a solid, and to a process for the preparation of such a complex. Complexes according to the invention are storage-stable and can be readily formulated in aqueous solution. | 2021-02-04 |
20210030714 | COMPOUNDS FOR USE IN THE TREATMENT OF BRAIN DISEASES - The present invention relates to a compound of formula (1): | 2021-02-04 |
20210030715 | ASCORBATE IN THE PREVENTION OF STATIN INDUCED VASCULAR CALCIFICATION - A method of treating or preventing vascular calcification in a patient by administering L-ascorbic acid or ascorbate to the patient and a pharmaceutical composition containing at least one statin and L-ascorbic acid or ascorbate in a dosage form that allows for the concomitant administering of the at least one statin and L-ascorbic acid or ascorbate to a patient. | 2021-02-04 |
20210030716 | ANTI-INFLAMMATORY COMPOSITION COMPRISING ACYLHYDRAZONE DERIVATIVE - The present invention relates to a composition for preventing, alleviating or treating inflammatory diseases, comprising, as an active ingredient, an acylhydrazone derivative compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. an acylhydrazone derivative compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of the present invention, effectively inhibits inflammatory cytokines and inflammatory signaling pathways, thereby effectively alleviating symptoms of inflammatory diseases such as dermatitis. Therefore, the composition according to the present invention may be effectively used for the prevention, alleviation or treatment of inflammatory diseases. | 2021-02-04 |
20210030717 | GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT PANCREATIC CANCER - Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor. | 2021-02-04 |
20210030718 | COMBINATIONS FOR TREATING CANCER - Disclosed are methods of treating cancer comprising administering 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6, 12,13,22-pentaazaheptacyclo[27.7.1.1 | 2021-02-04 |
20210030719 | GRP94 INHIBITORS TO TREAT STEROID-INDUCED OCULAR HYPERTENSIONS AND GLAUCOMAS - A method and composition for preventing, reducing, or treating steroid-induced ocular hypertension and steroid-induced glaucoma using a selective Grp94 inhibitor is presented. The Grp94-selective inhibitor can include methyl 2-(2-(1(4-bromobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate (4-Br—BnIm) or a derivative thereof. The Grp94-selective inhibitor can be administered prior to, during, or after administration of a steroid to the patient. | 2021-02-04 |
20210030721 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION - The present disclosure relates generally to compounds and pharmaceutical compositions for increasing glycosylation and treating congenital disorders of glycosylation. | 2021-02-04 |
20210030722 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase - The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives. | 2021-02-04 |
20210030723 | MODULATOR OF INDOLEAMINE 2,3-DIOXYGENASE, PREPARATION METHOD AND USE THEREOF - The present invention relates to a modulator of 1,2,5-oxadiazole indoleamine-(2,3)-dioxygenase, a preparation method and use thereof, more particularly to compounds of Formula I and Formula II, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, and their use in preparing drugs for treating cancers, neurodegenerative diseases, eye diseases, mental disorders, depression, anxiety disorders, Alzheimer's diseases and/or autoimmune diseases. Specific meanings of R substituents in Formula I and Formula II are consistent with the description of the specification. | 2021-02-04 |
20210030724 | Tizanidine Therapy System - An object of the present invention is to provide a method for the treatment of a patient suffering from spasticity comprising administering to said patient a modified release dosage form comprising tizanidine or a pharmaceutically acceptable salt thereof. | 2021-02-04 |
20210030725 | RESTORATION OF TRANSMEMBRANE COPPER TRANSPORT - Disclosed are methods of treating a disease or condition characterized by a deficiency of or a defect in a copper transporter using a small molecule. For example, the method may increase copper transport, or it may increase copper release. Additionally, the small molecule may be hinokitiol, or it may be selected from the group consisting of amphotericin B, calcimycin, nonactin, deferiprone, purpurogallin, and maltol. Also provided is a method of identifying a small molecule capable of treating a disease or condition characterized by a deficiency of or a defect in a copper transporter. | 2021-02-04 |
20210030726 | RAPAMYCIN ANALOG FOR PREVENTION AND/OR TREATMENT OF NEURODEGNERATIVE CONDITIONS - The present invention relates to a novel rapamycin analogue of Formula (I), mixtures, methods for its production, and its use in preventing and/or treating a neurodegenerative condition. | 2021-02-04 |
20210030727 | METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH GABOXADOL - Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X—associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder. | 2021-02-04 |
20210030728 | USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS - Methods and compositions for treating a metabolic disease include administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease. In embodiments, administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease is effective to lower one or more of HbA1c level, fasting plasma glucose level, 2-hour oral glucose tolerance test (OGTT) result level, and random plasma glucose level. Gaboxadol or a pharmaceutically acceptable salt thereof may optionally be administered in combination with a hypoglycemic agent. | 2021-02-04 |
20210030729 | NEW ANESTHETIC MIXTURES FORMULATIONS FOR LOCAL ANESTHESIA, AT VERY LOW CONCENTRATION, TO BE USED COLD WITH SUITABLE PACKAGING - Subject of the present invention is a diluted anesthetic solution, to be used cold, comprising the association of two different local anesthetics, one with a short duration of action and the other with a long duration of action and optionally in association with one or more adjuvant drugs having antibiotic, antifibrinolytic or antitumor action. With this association it is possible to prolong up to 150 m′ duration of action in addition to offering better management of perioperative problems both as a request for analgesic drugs for post-operative pain, but also as a support to alleviate and reduce complications in some way connected to certain surgical procedures. The invention concerns also specific packaging with specific formulations, such as to make the immediate use of the mixture itself possible for different interventions. | 2021-02-04 |
20210030730 | Methods Of Treating Fabry Patients Having Renal Impairment - Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day. | 2021-02-04 |
20210030731 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA - There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Q | 2021-02-04 |
20210030732 | ANTIARRHYTHMIC FORMULATION - Pharmaceutical compositions comprising an antiarrhythmic agent for treatment of a heart condition via inhalation. Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also disclosed. | 2021-02-04 |
20210030733 | COMPOSITIONS AND METHODS FOR SUSTAINED RELEASE OF FLECAINIDE - The invention relates generally to sustained release compositions. Specifically, the invention relates to biphasic and triphasic compositions and methods for controlling the release of a medication to treat a heart disease. | 2021-02-04 |
20210030734 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE - Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine. | 2021-02-04 |
20210030735 | PEDIATRIC NIRAPARIB FORMULATIONS AND PEDIATRIC TREATMENT METHODS - The present invention relates to methods of treating cancer in pediatric subjects comprising administration of compound niraparib in a suitable oral dosage form and optionally in combination with a second therapeutic agent such as a PD-1 inhibitor. | 2021-02-04 |
20210030736 | USE OF EZH2 INHIBITOR COMBINED WITH BTK INHIBITOR IN PREPARING DRUG FOR TREATING TUMOR - This application describes a use of an EZH2 inhibitor combined with a BTK inhibitor in preparing a drug for treating a tumor is described. | 2021-02-04 |
20210030737 | Triple Negative Breast Cancer Treatment Method - Disclosed is a method of treating triple negative breast cancer in a human patient, comprising administering to the patient an amount of cabozantinib or a pharmaceutically acceptable salt thereof, wherein the amount of cabozantinib is sufficient to activate the immune system. | 2021-02-04 |
20210030738 | ANTITUMOR AGENT AND ANTITUMOR EFFECT POTENTIATOR - The present invention is intended to provide a novel antitumor agent that shows marked antitumor effects with reduced side effects. The present invention relates to an antitumor agent characterized by coadministration of an acyl thiourea compound represented by general formula (I) or a salt thereof, and an immune checkpoint molecule regulator. | 2021-02-04 |
20210030739 | COMPOSITIONS AND METHODS OF TREATING CANCER - The disclosure is directed to methods of treating cancer in subjects with a combination of a monoclonal antibody and (R)-N-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide, or a salt thereof. | 2021-02-04 |
20210030740 | B CELL LYMPHOMA 6 PROTEIN (BCL6) AS A TARGET FOR TREATING DIABETES MELLITUS AND NON-ALCOHOLIC FATTY LIVER DISEASE - Disclosed are methods and compositions for treating diabetes mellitus and non-alcoholic fatty liver disease by administering a therapeutic agent that inhibits the biological activity of B cell lymphoma 6 protein (BCL6). | 2021-02-04 |
20210030741 | PHARMACEUTICAL COMBINATION OF EVEROLIMUS WITH DACTOLISIB - The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto. | 2021-02-04 |
20210030742 | Methods for the Administration of Certain VMAT2 Inhibitors - Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer. | 2021-02-04 |
20210030743 | High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto - Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate. | 2021-02-04 |
20210030744 | High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto - Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate. | 2021-02-04 |
20210030745 | Methods and Compositions for Treating Vasomotor Symptoms - The present disclosure is generally directed to compositions and methods for treating or limiting development of vasomotor symptoms in a subject. | 2021-02-04 |
20210030746 | METHODS AND COMPOSITIONS FOR TREATING CANCER - This disclosure relates to methods and compositions for treating cancer by administering opioid growth factor receptor (OGFR) antagonists. In particular, the present disclosure relates to methods of administering OGFR antagonists locally to the site of cancer cells in the patient diagnosed with cancer. | 2021-02-04 |
20210030747 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2021-02-04 |
20210030749 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2021-02-04 |
20210030750 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2021-02-04 |
20210030751 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2021-02-04 |
20210030752 | TREATING COGNITIVE DECLINE AND OTHER NEURODEGENERATIVE CONDITIONS BY SELECTIVELY REMOVING SENESCENT CELLS FROM NEUROLOGICAL TISSUE - Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. | 2021-02-04 |
20210030753 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors - The present invention provides methods for inhibiting Fyn kinase, using 5-3-pyridin-2-amine, 6-3-imidazo[1,2-a] pyrazine, 6-3-imidazo[1,2-b] pyridazine, N-(5-imidazo [2,1-b][1,3,4] thiadiazol-2-yl)-amine, 4-3-1H-pyrazolo[3,4-b] pyridine, and N-(3-imidazo [1,2-b] pyridazin-6-yl) amine compounds and methods of treatment, prevention, inhibition or amelioration of diseases and conditions associated with Fyn kinase using such compounds. | 2021-02-04 |
20210030754 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF - Provided are a compound that is useful for the prevention of and/or as a treatment agent for a disease in which a group II mGlu receptor is involved; and a medical application of said compound. Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. | 2021-02-04 |
20210030755 | PHARMACEUTICAL COMPOSITION INCLUDING SODIUM ALKYL SULFATE - The object of the present invention is to improve the dissolution and the absorption of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl-1-pyrrolidinyl)-2-propen-1-one effective as an antitumor agent from a pharmaceutical formulation comprising the same. Provided is a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl-1-pyrrolidinyl)-2-propen-1-one in combination with sodium alkyl sulfate having an alkyl group containing 10 to 18 carbon atoms, in particular, with sodium lauryl sulfate. | 2021-02-04 |
20210030756 | CHIRAL DIARYL MACROCYCLES AND USES THEREOF - This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans. | 2021-02-04 |
20210030757 | METHOD OF TREATMENT AND COMPOSITIONS COMPRISING A DUAL P13K DELTA-GAMMA KINASE INHIBITOR AND A CORTICOSTEROID - This present disclosure relates to a method of treating autoimmune, respiratory and/or inflammatory diseases or conditions, e.g., asthma, COPD, rheumatoid arthritis and idiopathic pulmonary fibrosis (IPF). The method comprises administering a dual PI3K delta and gamma inhibitor and a corticosteroid. The present invention also relates to pharmaceutical compositions containing a dual PI3K delta and gamma inhibitor and a corticosteroid. | 2021-02-04 |
20210030758 | TREATMENT OF CANCERS HAVING DRIVING ONCOGENIC MUTATIONS - Methods and compositions are described to treat a cancer having a specific oncogenic driving mutation by administering a CDK4/6 inhibitor in combination with an additional kinase inhibitor, wherein the specific combination provides advantageous or synergistic inhibitory activity, delays acquired resistance to the additional kinase inhibitor, and/or extends the efficacy of the kinase inhibitor. | 2021-02-04 |
20210030759 | METHOD FOR TREATING CANCER USING HSP90 INHIBITORS - The disclosure also provides compositions and methods related to combination therapy with HSP90 inhibitors and BCL-2 pathway inhibitors for treating cancer. The disclosure also provides compositions and methods related to the use of ‘low dose’ HSP90 inhibitors in the treatment of cancer, alone and in combination with other therapeutic agents. | 2021-02-04 |
20210030760 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS - The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example an addiction or compulsive disorder. | 2021-02-04 |
20210030761 | TREATMENT AND PREVENTION OF ALPHA HERPES VIRUS INFECTION - Methods for decreasing or inhibiting herpesviridae (HV) infection, or pathogenesis of a cell, or a symptom, or pathology associated with a herpesviridae (HV) infection or pathogenesis or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo, or in vivo. These methods include treating a subject with an NK-1 receptor antagonist. | 2021-02-04 |
20210030762 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE - Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof. | 2021-02-04 |
20210030763 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS - The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis. | 2021-02-04 |
20210030764 | METHOD OF TREATING CANCER - Disclosed herein is a method of treating patients with NSCLC subtypes of cancer by reducing tumor burden, comprising administering at least one dose of purified Ruthenium (III) Pyrazole complexes to patients suffering from NSCLC, wherein said dose is therapeutically sufficient. In one or more embodiments, the Ruthenium III Pyrazole is RuCl | 2021-02-04 |
20210030765 | HEMATOPOIESIS-ENHANCING AGENT - The purpose of the invention is to provide a novel hematopoiesis-promoting agent and a medicament comprising the hematopoiesis-promoting agent as an active ingredient for preventing or treating anemia, in particular refractory anemia. The present invention provides a hematopoiesis-promoting agent comprising an S-adenosylmethionine synthase inhibitor. | 2021-02-04 |
20210030766 | PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANTS AND METHODS OF USE THEREOF - Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described. | 2021-02-04 |